跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 2026-10-09AI 评分56

Revolution Medicines的Rasonque胰腺癌新数据:常见KRAS突变患者响应率或低于总体人群

New data on RevMed’s Rasonque leave potential opening for other treatments

AI 导读

接受Revolution Medicines的Rasonque治疗的胰腺癌患者中,携带最常见KRAS突变的患者响应率似乎低于总体人群;报道认为这或为其他治疗留下空间。

正文

Pan­cre­at­ic can­cer pa­tients with the most com­mon KRAS mu­ta­tion ap­peared to have a low­er re­sponse rate than the over­all pa­tient pop­u­la­tion with Rev­o­lu­tion Med­i­cines’ Ra­sonque …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news